Abstract
BACKGROUND AND AIMS: Hepatitis C virus (HCV) infection is common among hemodialysis (HD) patients and is associated with increased morbidity and mortality. Aim of the study is to assess the safety and efficacy of pangenotypic DAA regimens in patients with chronic disease on maintenance hemodialysis. In thisMATERIALS AND METHODS: prospective observational study, hemodialysis patients with chronic hepatitis C infection were identified and treatment initiated with appropriate pangenotypic regimen. Totally 74 patients diagnosed with chronic hepatitis C and treated with DAAs for 12 weeks. The sustained virologic response (SVR) rate obtained 12 weeks post-treatment (SVR12) was evaluated. Laboratory indices and adverse reactions during the treatment process were also assessed. All theRESULTS: patients enrolled completed 12 weeks of treatment. 12 out of 74(16.2%) patients had compensated liver disease. SVR was achieved in 12 out of 12 patients (100%) receiving sofosbuvir/velpatasvir, and 60 of 62 patients (96.7%) receiving sofosbuvir/daclatasvir. No serious or significant adverse reactions were reported. PangenotypicCONCLUSION: regimens containing sofosbuvir are safe and well tolerated in patients with chronic kidney disease on maintenance hemodialysis. Sofosbuvir/daclatasvir based regimens at full dose can be used as an alternative pan genotypic regimen in patients with chronic kidney disease on hemodialysis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
